Related Experiment Video
Updated: Apr 29, 2026
14:23
A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
Published on: August 31, 2014
15.2K
The Pediatric AIDS Corps: a 5-year evaluation.
Pediatrics
|May 28, 2014
Summary
The Pediatric AIDS Corps (PAC) significantly expanded HIV care for children and trained healthcare professionals in resource-limited areas. Its success supports developing a national global health corps program.
Area of Science:
- Global Health
- Pediatric HIV/AIDS
- Health Workforce Development
Background:
- The Pediatric AIDS Corps (PAC) was established in June 2005 by the Baylor College of Medicine International Pediatric AIDS Initiative.
- This report details the PAC's activities and outcomes during its initial five years of operation.
Purpose of the Study:
- To describe the demographic characteristics and experiences of physicians participating in the Pediatric AIDS Corps.
- To evaluate the impact of the PAC on HIV care and education in resource-limited settings.
Main Methods:
- Demographic data were collected for PAC physicians from July 2006 to June 2011.
- A 21-question survey assessed physician experiences within the program.
- Clinical and educational program data were also reviewed.
Main Results:
- 128 physicians served with the PAC, with a median tenure of 22.7 months.
- 87% reported the experience influenced their future career choices, with half continuing work in resource-limited areas.
- Enrollment of HIV-infected children increased from 6,107 to 103,731; approximately 500 local professionals received HIV training quarterly.
- 37% of outreach sites became self-sufficient due to PAC physician mentoring.
Conclusions:
- Physician evaluations and program scale-up suggest the effectiveness of the PAC model.
- Findings support the establishment of a national global health corps program to address healthcare needs in underserved regions.
Related Concept Videos
01:16Clinical Trials
8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.5K
01:11Clinical Trials: Overview
4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
404
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
404
01:12Hazard Ratio
754
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
754
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
409
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
409
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
960
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
960